Stable protein solution formulation containing high concentration of an anti-VEGF antibody
The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.
1. An aqueous pharmaceutical composition, comprising (i) 60 mg/ml to 120 mg/ml of an anti-VEGF antibody that comprises the sequences of SEQ ID NO: 1 and SEQ ID NO: 2, (ii) 4.5% to 9% (w/v) sucrose, (iii) a citrate buffer comprising 0.006% to 0.012% (w/v) citric acid and 0.2% to 0.6% trisodium citrate dihydrate (w/v), and (iv) 0.01% to 0.1% polysorbate 80, wherein the aqueous pharmaceutical composition is suitable for ophthalmic administration.
2. The aqueous pharmaceutical composition of claim 1 , having a pH of 6.3 to 7.3.
3. The aqueous pharmaceutical composition of claim 2 , wherein the pH of the composition is about 6.8.
4. The aqueous pharmaceutical composition of claim 1 , wherein the antibody comprises the sequence of SEQ ID NO: 3.
5. The aqueous pharmaceutical composition of claim 1 , wherein the concentration of the anti-VEGF antibody is about 60 mg/ml.
6. The aqueous pharmaceutical composition of claim 1 , wherein the concentration of the anti-VEGF antibody is about 120 mg/ml.
7. A delivery device including the aqueous pharmaceutical composition of claim 1 .
8. The delivery device of claim 7 , which is a pre-filled syringe.
9. A pre-filled syringe comprising an aqueous pharmaceutical composition that comprises (i) 60 mg/ml to 120 mg/ml of an anti-VEGF antibody that comprises the sequences of SEQ ID NO: 1 and SEQ ID NO: 2, (ii) 4.5% to 9% (w/v) sucrose, (iii) a citrate buffer comprising 0.006% to 0.012% (w/v) citric acid and 0.2% to 0.6% trisodium citrate dihydrate (w/v), and (iv) 0.01% to 0.1% polysorbate 80, wherein the aqueous pharmaceutical composition is suitable for ophthalmic administration.
10. The pre-filled syringe of claim 9 , wherein the aqueous pharmaceutical composition has a pH of 6.3 to 7.3.
11. The pre-filled syringe of claim 9 , wherein the antibody comprises the sequence of SEQ ID NO: 3.
12. The pre-filled syringe of claim 9 , wherein the concentration of the anti-VEGF antibody is about 60 mg/ml.
13. The pre-filled syringe of claim 9 , wherein the concentration of the anti-VEGF antibody is about 120 mg/ml.
14. An aqueous pharmaceutical composition, comprising (i) about 60 mg/ml or about 120 mg/ml of an anti-VEGF antibody that comprises the sequences of SEQ ID NO: 1 and SEQ ID NO: 2, (ii) 4.5% to 9% (w/v) sucrose, (iii) a citrate buffer comprising 10 mM to 20 mM citrate, and (iv) 0.01% to 0.05% polysorbate 80, wherein the aqueous pharmaceutical composition is suitable for ophthalmic administration.